Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
C 273.24 0.13% 0.36
BIIB closed up 0.13 percent on Monday, March 1, 2021, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Up Down
Historical BIIB trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Fell Below 200 DMA Bearish 0.13%
Fell Below 20 DMA Bearish 0.13%
MACD Bearish Signal Line Cross Bearish -1.45%
20 DMA Support Bullish -1.45%
Spinning Top Other -2.09%
Older End-of-Day Signals for BIIB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 8 hours ago
Rose Above 20 DMA about 8 hours ago
60 Minute Opening Range Breakout about 8 hours ago
Up 1% about 8 hours ago
200 DMA Support about 11 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biogen Idec Inc. Description

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biotechnology Immunology Pain Disability Monoclonal Antibodies Monoclonal Antibody Lymphoma Alzheimer's Disease Multiple Sclerosis Psoriasis Degenerative Disease Specialty Drugs Degenerative Diseases Immune Disorders Hemophilia Neurodegenerative Diseases Neuropathic Pain Chronic Lymphocytic Leukemia Idiopathic Pulmonary Fibrosis Lymphocytic Leukemia Progressive Pulmonary Fibrosis Autoimmune Disorders Weston Lupus Clinical Trial Product Spinal Muscular Atrophy Immunosuppressants Interferon Cd20 Factor Vii Treatment Of Hemophilia Acorda Therapeutics Clinical Trial Products Lupus Nephritis Nephritis Plaque Psoriasis Portola Pharmaceuticals

Is BIIB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 363.92
52 Week Low 223.25
Average Volume 1,274,629
200-Day Moving Average 272.65
50-Day Moving Average 265.34
20-Day Moving Average 275.10
10-Day Moving Average 278.01
Average True Range 8.05
ADX 25.99
+DI 24.43
-DI 17.23
Chandelier Exit (Long, 3 ATRs ) 272.22
Chandelier Exit (Short, 3 ATRs ) 285.18
Upper Bollinger Band 286.25
Lower Bollinger Band 263.95
Percent B (%b) 0.42
BandWidth 8.11
MACD Line 2.94
MACD Signal Line 3.90
MACD Histogram -0.9676
Fundamentals Value
Market Cap 42.05 Billion
Num Shares 154 Million
EPS 30.38
Price-to-Earnings (P/E) Ratio 8.99
Price-to-Sales 2.86
Price-to-Book 3.49
PEG Ratio 6.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 279.50
Resistance 3 (R3) 279.61 277.63 278.46
Resistance 2 (R2) 277.63 276.03 277.57 278.11
Resistance 1 (R1) 275.43 275.05 274.44 275.33 277.76
Pivot Point 273.45 273.45 272.96 273.40 273.45
Support 1 (S1) 271.26 271.86 270.27 271.15 268.72
Support 2 (S2) 269.28 270.87 269.22 268.37
Support 3 (S3) 267.08 269.28 268.02
Support 4 (S4) 266.98